The Journal of Bone and Joint Surgery (American). 2009;91:2020-2027.

Nonsteroidal Anti-Inflammatory Drugs in Orthopaedics

Omar Abdul-Hadi, MD1, Javad Parvizi, MD2, Matthew S. Austin, MD2, Eugene Viscusi, MD3 and Thomas Einhorn, MD4
1 Southern Oregon Orthopedics, 2780 East Barnett Road, Suite 200, Medford, OR 97504. E-mail address: ortho75 at gmail.com
2 Rothman Institute of Orthopedics at Thomas Jefferson University, 925 Chestnut Street, 5th Floor, Philadelphia, PA 19107
3 Department of Anesthesiology, Thomas Jefferson University Hospital, 524 Main Building, 132 South 10th Street, Philadelphia, PA 19107
4 Department of Orthopaedic Surgery, Boston University Medical Center, 720 Harrison Avenue, Suite 808, Boston, MA 02118

An Instructional Course Lecture, American Academy of Orthopaedic Surgeons

Introduction
Nonsteroidal anti-inflammatory drugs are widely used and prescribed in the United States. Between 35 and 70 million prescriptions for nonsteroidal anti-inflammatory drugs are written in the United States each year, and numerous agents are now available over the counter1. In particular, the prescription of cyclooxygenase-2 (COX-2) inhibitors has become widespread since they were approved by the U.S. Food and Drug Administration in 1999, and in 2000 nearly 45 million prescriptions were written for celecoxib and rofecoxib2. More than 17 million Americans use various nonsteroidal anti-inflammatory drugs on a daily basis. Moreover, it has been estimated that 5% to 7% of all hospital admissions are related to adverse drug reactions, with nonsteroidal anti-inflammatory drugs being the culprit in 30% of these cases3. As a result of the aging of the population, there will be an increase in the use of nonsteroidal anti-inflammatory drugs parallel to the increase in . . .

I just finished reading the full-text and it is definitely worth purchasing --> click here.

© 2009 The Journal of Bone and Joint Surgery, Inc.